ArticlePsychiatric services (Washington, D.C.)2021
Changes in Buprenorphine Treatment After Medicaid Expansion.
Article in Psychiatric services (Washington, D.C.), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 21 citations in OpenAlex.
- Buprenorphine utilization following removal of prior authorization requirements in the Kentucky Medicaid population.Drug and alcohol dependence · 2026Article
- Medicaid Expansion and Buprenorphine Dispensing in Early vs Recent Expansion States.JAMA network open · 2026Article
- Clinical strategies for low-dose overlap initiation of buprenorphine and potential barriers to use.The mental health clinician · 2025Article
- States With Substantial Increases In Buprenorphine Uptake Did So With Increased Medicaid Prescribing, 2018-24.Health affairs (Project Hope) · 2025Article
- Mental health behaviors and suicide risk among White and Black adults with Opioid Use Disorder.Social science & medicine (1982) · 2025Article
- Changes in legal referrals to specialty substance use disorder treatment from 2015-2019.Health & justice · 2024Article
- Buprenorphine use among non-hospital residential programs.Drug and alcohol dependence · 2024Article
- Treatment setting and buprenorphine discontinuation: an analysis of multi-state insurance claims.Addiction science & clinical practice · 2024Observational
- Differences in medicaid expansion effects on buprenorphine treatment utilization by county rurality and income: A pharmacy data claims analysis from 2009-2018.Drug and alcohol dependence reports · 2023Article
- State Policy and the Breadth of Buprenorphine-Prescriber Networks in Medicaid Managed Care.Medical care research and review : MCRR · 2023Article
- National Trends in Buprenorphine Treatment for Opioid Use Disorder From 2007 to 2018.Substance abuse · 2023Observational
- Exploring the Association of State Policies and the Trajectories of Buprenorphine Prescriber Patient Caseloads.Substance abuse · 2023Article
- Association of Selected State Policies and Requirements for Buprenorphine Treatment With Per Capita Months of Treatment.JAMA health forum · 2023Article
- Medicaid Managed Care: Access To Primary Care Providers Who Prescribe Buprenorphine.Health affairs (Project Hope) · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
objectiveThe authors examined changes in buprenorphine treatment following Medicaid expansion, including the contribution of Medicaid-financed prescriptions.
methodsBuprenorphine pharmacy claims for patients were identified in the 2012-2018 IQVIA Longitudinal Prescription Data (LRx) data set, including 79.8% of U.S. retail prescriptions in 2012, increasing to 92.0% in 2018. A cohort analysis was used to assess the mean number of patients in a yearly quarter filling one or more buprenorphine prescriptions during preexpansion (2012-2013) and postexpansion (2014-2018) periods in expansion and nonexpansion states. Interrupted time-series analysis estimated associations of Medicaid expansion period with change in Medicaid-financed treatment. Separate analyses evaluated changes in duration and dose of new treatment episodes focused on mean quarterly number of patients treated with buprenorphine and proportions of new treatment episodes ≥180 days long and with ≥16 mg/day.
resultsBetween preexpansion and postexpansion, the mean quarterly number of patients taking buprenorphine increased by 93,300 in expansion states and by 84,960 in nonexpansion states. Corresponding changes for Medicaid-financed patients were 28,760 and 4,050, respectively. The fastest growth in Medicaid-financed treatment occurred among patients ages 25-44. Among new Medicaid-financed treatment episodes, little change was found in the proportion reaching the 180-day threshold, and declines were observed in the proportion receiving ≥16 mg/day.
conclusionsThe findings are consistent with previous research indicating that Medicaid expansion has increased Medicaid-financed buprenorphine treatment. However, because of offsetting changes in other payment groups, the overall increase in expansion states was similar to the increase in nonexpansion states.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.